Texto: 
External examination: Bilateral superotemporal firm, non-mobile subconjunctival masses with dilated vasculature; 3.5 mm right proptosis; full ductions, no diplopia

Internal examination: 2-3+ Nuclear sclerotic cataracts O.U. resulting in 20/40 â€“ 20/50 best corrected VA; Choroidal nevus, unchanged for 15 years
May 2004:
Rx: Thalidomide
Shrinkage of orbital masses

March 2005:
Clinical examination: recurrence right orbit
Rx: Liposomal vincristine

November 2005:
No evidence of orbital disease
Biopsies of right orbital lobe of lacrimal gland and right subconjunctival mass.

Histopathology: Monomorphous centrocyte-like small lymphocytes, Cyclin D1 + [IHC]

Flow cytometry: CD5/CD20 +,CD10, CD23 â€“, FMC7 +

Cytogenetics: t(11;14)(q12-13.1;q32)
Mantle Cell Lymphoma
70-year-old female with â€˜swollen eyelidsâ€™ and pain on abduction of right eye x 4 days.

Remote history of breast (age 46) and ovarian (age 28) cancer.

1999: Mantle cell lymphoma, periaortic lymph nodes/ileocecal valve/bone marrow: CHOP, Hyper CVAD. Autologous stem cell transplant 2002. No chemotherapy since January 2004
Recently defined category of B-cell lymphomas (3-10%).

Clinical features:
Late adulthood (median age 60)
Male predominance
Multifocal lymphadenopathy, hepatosplenomegaly, bone marrow involvement
GI tract, Waldeyerâ€™s ring also common extranodal sites
Median survival 3-5 years

Cell of origin: â€˜mantle cellâ€™ immediately surrounding follicle:
â€˜Centrocyte-likeâ€™ morphology
Proliferative in monotonous sheets of small cells with irregular nuclear contours, inconspicuous nucleoli
Hyalinized capillaries

Immunophenotype:
B-cell lymphocyte
CD19+, CD20+
Coexpression of CD5 (CD5+/CD20+)
DDx: SLL/CLL
Negative for:
CD23 (CLL/SLL CD5+,CD23+)
CD10 (FL CD5-,CD10+); (MALT CD5-,CD10-)
Cyclin D1+, FMC7+

Cytogenetics:
t(11;14) (q13;q32)
Juxtaposition of Ig heavy chain promoter and Cyclin D1 gene
Overexpression of Cyclin D1 gene, increased mRNA, gene product
Promotes phosphorylation of pRB, passage of cell into S phase

Ocular adnexal involvement:
Rare: eyelid, conjunctiva, orbit, lacrimal gland
3-5% of all ocular adnexal lymphomas
Demographics
Age > 60
M >> F
Aggressive behavior
Median survival < 5 years
Largest series: White, Rootman et al
10 cases: 
9 with multiple periocular sites
6 bilateral
9 orbital, 5 lacrimal gland, 5 eyelid
8 periocular presenting site
Unusual findings
3 cases CD5 â€“
2 cases composite lymphomas
Mantle cell/follicular lymphoma
Mantle cell/plasma cell neoplasm


Keywords: 
\-\ 5\\ eyelid\\ 8\\ periocular\\ presenting\\ site\\ unusual\\ findings\\ 3\\ cases\\ cd5\\ \\â\\€\\“\\ 2\\ cases\\ composite\\ lymphomas\\ mantle\\ cell\ \(0\)\
\-\ ring\\ also\\ common\\ extranodal\\ sites\\ median\\ survival\\ 3\ \(0\)\
\-\ malt\\ cd5\\ \\-\\,\\ cd10\\ \\-\\)\\ cyclin\\ d1\\ \\+\\,\\ fmc7\ \(0\)\
\-\ chemotherapy\\ since\\ january\\ 2004\\ recently\\ defined\\ category\ \(0\)\
\-\ multiple\\ periocular\\ sites\\ 6\\ bilateral\\ 9\\ orbital\ \(0\)\
\-\ \\â\\€\\˜\\ mantle\\ cell\\ \\â\\€\\™\\ immediately\\ surrounding\\ follicle\ \(0\)\
\-\ \\>\\>\\ f\\ aggressive\\ behavior\\ median\\ survival\ \(0\)\
\-\ rootman\\ et\\ al\\ 10\\ cases\ \(0\)\
\-\ sll\\ cd5\\ \\+\\,\\ cd23\\ \\+\\)\\ cd10\ \(0\)\
\-\ fl\\ cd5\\ \\-\\,\\ cd10\\ \\+\\)\\;\ \(0\)\
\-\ cd5\\ \\+\\/\\ cd20\\ \\+\\)\\ ddx\ \(0\)\
\-\ ocular\\ adnexal\\ lymphomas\\ demographics\\ age\ \(0\)\
\-\ cell\\ lymphocyte\\ cd19\\ \\+\\,\\ cd20\ \(0\)\
\-\ inconspicuous\\ nucleoli\\ hyalinized\\ capillaries\\ immunophenotype\ \(0\)\
\-\ autologous\\ stem\\ cell\\ transplant\\ 2002\ \(0\)\
\-\ right\\ eye\\ x\\ 4\\ days\ \(1\)\
\-\ bone\\ marrow\\ involvement\\ gi\\ tract\ \(0\)\
\-\ mantle\\ cell\\ lymphoma\\ 70\ \(0\)\
\-\ follicular\\ lymphoma\\ mantle\\ cell\ \(0\)\
\-\ phase\\ ocular\\ adnexal\\ involvement\ \(0\)\
\-\ 5\\ mm\\ right\\ proptosis\ \(1\)\
\-\ 5\\ years\\ largest\\ series\ \(0\)\
\-\ 15\\ years\\ may\\ 2004\ \(0\)\
\-\ cyclin\\ d1\\ gene\\ overexpression\ \(0\)\
\-\ \\â\\€\\˜\\ swollen\\ eyelids\\ \\â\\€\\™\ \(0\)\
\-\ male\\ predominance\\ multifocal\\ lymphadenopathy\ \(0\)\
\-\ liposomal\\ vincristine\\ november\\ 2005\ \(0\)\
\-\ ig\\ heavy\\ chain\\ promoter\ \(0\)\
\-\ 50\\ best\\ corrected\\ va\ \(0\)\
\-\ mantle\\ cell\\ lymphoma\ \(1\)\
\-\ cd20\\ \\+\\,\\ cd10\ \(0\)\
\-\ orbital\\ masses\\ march\\ 2005\ \(0\)\
\-\ like\\ \\â\\€\\™\\ morphology\\ proliferative\ \(0\)\
\-\ gene\\ product\\ promotes\\ phosphorylation\ \(0\)\
\-\ 40\\ \\â\\€\\“\\ 20\ \(1\)\
\-\ 5\\ years\\ cell\ \(0\)\
\-\ cell\\ lymphomas\ \(2\)\
\-\ lacrimal\\ gland\\ 3\ \(0\)\
\-\ recurrence\\ right\\ orbit\\ rx\ \(0\)\
\-\ cyclin\\ d1\\ gene\ \(0\)\
\-\ cd23\\ \\â\\€\\“\\,\\ fmc7\ \(0\)\
\-\ right\\ orbital\\ lobe\ \(1\)\
\-\ plasma\\ cell\\ neoplasm\ \(1\)\
\-\ bilateral\\ superotemporal\\ firm\ \(0\)\
\-\ 5\\ lacrimal\\ gland\ \(1\)\
\-\ median\\ age\\ 60\ \(1\)\
\-\ orbital\\ disease\\ biopsies\ \(0\)\
\-\ right\\ subconjunctival\\ mass\ \(1\)\
\-\ mobile\\ subconjunctival\\ masses\ \(1\)\
\-\ eyelid\ \(38\)\
\-\ 2\ \(13754\)\
\-\ periaortic\\ lymph\\ nodes\ \(2\)\
\-\ nuclear\\ sclerotic\\ cataracts\ \(0\)\
\-\ like\\ small\\ lymphocytes\ \(1\)\
\-\ irregular\\ nuclear\\ contours\ \(1\)\
\-\ cyclin\\ d1\ \(0\)\
\-\ diplopia\\ internal\\ examination\ \(0\)\
\-\ 14\\ \\)\\(\\ q12\ \(0\)\
\-\ 3\ \(8405\)\
\-\ cd5\ \(0\)\
\-\ bone\\ marrow\ \(115\)\
\-\ \\â\\€\\˜\\ centrocyte\ \(0\)\
\-\ waldeyer\\ \\â\\€\\™\ \(0\)\
\-\ 5\ \(8237\)\
\-\ 10\\ \\%\\)\\.\ \(0\)\
\-\ lacrimal\\ gland\ \(27\)\
\-\ cell\ \(1589\)\
\-\ age\\ 46\ \(1\)\
\-\ age\\ 28\ \(2\)\
\-\ small\\ cells\ \(1\)\
\-\ external\\ examination\ \(0\)\
\-\ clinical\\ examination\ \(9\)\
\-\ thalidomide\\ shrinkage\ \(0\)\
\-\ remote\\ history\ \(12\)\
\-\ old\\ female\ \(547\)\
\-\ monotonous\\ sheets\ \(1\)\
\-\ monomorphous\\ centrocyte\ \(0\)\
\-\ late\\ adulthood\ \(2\)\
\-\ increased\\ mrna\ \(0\)\
\-\ ileocecal\\ valve\ \(18\)\
\-\ hyper\\ cvad\ \(0\)\
\-\ full\\ ductions\ \(1\)\
\-\ flow\\ cytometry\ \(4\)\
\-\ dilated\\ vasculature\ \(1\)\
\-\ clinical\\ features\ \(7\)\
\-\ choroidal\\ nevus\ \(0\)\
\-\ 9\ \(4978\)\
\-\ sll\ \(1\)\
\-\ cll\\ negative\ \(0\)\
\-\ cd23\ \(0\)\
\-\ rx\ \(6\)\
\-\ orbit\ \(430\)\
\-\ 60\ \(445\)\
\-\ 20\ \(2416\)\
\-\ 14\ \(608\)\
\-\ cll\ \(0\)\
\-\ year\ \(4238\)\
\-\ white\ \(522\)\
\-\ unchanged\ \(35\)\
\-\ u\ \(158107\)\
\-\ resulting\ \(195\)\
\-\ rare\ \(447\)\
\-\ q32\ \(2\)\
\-\ q13\ \(1\)\
\-\ prb\ \(0\)\
\-\ passage\ \(38\)\
\-\ pain\ \(4766\)\
\-\ ovarian\ \(217\)\
\-\ origin\ \(369\)\
\-\ non\ \(1889\)\
\-\ juxtaposition\ \(1\)\
\-\ ihc\ \(0\)\
\-\ histopathology\ \(4\)\
\-\ hepatosplenomegaly\ \(25\)\
\-\ evidence\ \(994\)\
\-\ cytogenetics\ \(0\)\
\-\ conjunctiva\ \(22\)\
\-\ coexpression\ \(0\)\
\-\ chop\ \(47\)\
\-\ cancer\ \(694\)\
\-\ breast\ \(862\)\
\-\ b\ \(71376\)\
\-\ abduction\ \(30\)\
\-\ 1999\ \(73\)\
\-\ 13\ \(747\)\
\-\ 11\ \(860\)\
\-\ 1\ \(15898\)\
